Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

41.33 +7.51 (+22.19%)

Streaming Delayed Price Updated: 3:32 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Wednesday's session: top gainers and losers ↗

Today 13:30 EDT

Via Chartmill

What's Behind The Jump In Corcept Therapeutics Stock? ↗

Today 12:06 EDT

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary...

Via Benzinga

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 22, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Corcept Therapeutics Inc (NASDAQ:CORT): A GARP Pick with Accelerating Growth and a Solid Financial Base ↗

March 18, 2026

Via Chartmill

1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid

March 11, 2026

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...

Via StockStory

Topics Credit Cards

Corcept Therapeutics (NASDAQ:CORT) Stock Falls After Q4 Earnings Miss Estimates ↗

February 24, 2026

Via Chartmill

Topics Earnings

Corcept Therapeutics Inc (NASDAQ:CORT) Presents a Compelling GARP Investment Case ↗

February 16, 2026

Via Chartmill

CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst ↗

February 25, 2026

The company guided for $900 million to $1 billion in 2026 revenue.

Via Stocktwits

Corcept (NASDAQ:CORT) Misses Q4 CY2025 Sales Expectations

February 24, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 11.1% year on year to $202.1 million. Its GAAP profit of $0.20 per...

Via StockStory

Topics Artificial Intelligence Supply Chain

Corcept (CORT) Q4 Earnings: What To Expect

February 22, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence World Trade

CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight ↗

February 19, 2026

The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome.

Via Stocktwits

Topics Intellectual Property

Corcept Therapeutics Inc (NASDAQ:CORT) Fits the Affordable Growth Profile ↗

January 23, 2026

Via Chartmill

3 Small-Cap Stocks We Think Twice About

February 16, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

3 Cash-Producing Stocks We’re Skeptical Of

February 15, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Inspire Medical Systems, Astrana Health, Evolent Health, Corcept, and Centene Stocks Trade Up, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Via StockStory

Topics Economy

3 Profitable Stocks with Warning Signs

February 03, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say ↗

January 30, 2026

As per the letter published by the FDA, the agency had alerted the company regarding its concerns for Relacorilant before.

Via Stocktwits

What's going on in today's after hours session ↗

January 29, 2026

Via Chartmill

Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology

January 28, 2026

As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused...

Via Finterra

Topics Economy Intellectual Property

2 Stocks Under $50 to Target This Week and 1 We Turn Down

January 26, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗

January 22, 2026

In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.

Via Stocktwits

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 22, 2026

Via Chartmill

1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 Facing Headwinds

January 21, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

1 Safe-and-Steady Stock to Target This Week and 2 That Underwhelm

January 19, 2026

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Corcept Insider Transaction Explained After Shares Tumble 50% in One Day ↗

January 11, 2026

Focused on therapies for endocrine and oncologic conditions, this biotech reported significant insider selling in its latest SEC filing.

Via The Motley Fool

Topics Regulatory Compliance

1 Healthcare Stock to Target This Week and 2 We Turn Down

January 05, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 17.2% over...

Via StockStory

Topics Stocks

Why Corcept (CORT) Stock Is Trading Lower Today

January 05, 2026

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.5% in the morning session after the company’s stock faced continued selling pressure following the U.S. Food and Drug...

Via StockStory

In today's session, these stocks are experiencing unusual volume. ↗

January 02, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Point To Strong New-Year Open On Wall Street: Why TSLA, BIDU, SLV, STLA Are On Traders' Radar Today ↗

January 02, 2026

Via Stocktwits

Topics Stocks

Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio

January 01, 2026

Check out the companies making headlines yesterday:

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.